Payment overview · 2025
General Payments
$741.74
37 reported records · 16 companies
Healthcare provider profile · identity verified
Thomas E Edwards, MD
Allopathic & Osteopathic Physicians|Family Medicine · THOMASVILLE, GA · NPI 1558599159
Verified facts
What the public records show
CMS Open Payments records show Thomas E Edwards, MD received $741.74 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.69 | 12.0% | 5 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $77.49 | 10.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $73.97 | 10.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.11 | 9.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.04 | 8.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.43 | 7.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.50 | 7.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.32 | 6.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.44 | 6.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.57 | 5.7% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $30.63 | 4.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $28.39 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.15 | 2.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.85 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.61 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.55 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $741.74 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $77.49 | 4 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $77.49 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $73.97 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $72.11 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $72.11 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.20 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.32 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $30.63 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 106 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 176 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
45 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 401 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 102 |
| Losartan Potassium | Losartan Potassium | 337 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 92 |
| Lisinopril | Lisinopril | 302 | 85 |
| Omeprazole | Omeprazole | 258 | 76 |
| Gabapentin | Gabapentin | 234 | 64 |
| Trazodone Hcl | Trazodone Hcl | 214 | 57 |
| Metformin Hcl | Metformin Hcl | 203 | 49 |
| Sertraline Hcl | Sertraline Hcl | 187 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 53 |
| Ozempic | Semaglutide | 176 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 168 | 127 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 44 |
| Jardiance | Empagliflozin | 154 | 39 |
| Lorazepam | Lorazepam | 154 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 44 |
| Furosemide | Furosemide | 139 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 44 |
| Mirtazapine | Mirtazapine | 130 | 36 |
| Tramadol Hcl | Tramadol Hcl | 128 | 39 |
| Potassium Chloride | Potassium Chloride | 127 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 35 |
| Linzess | Linaclotide | 116 | 33 |
| Eliquis | Apixaban | 115 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 33 |
| Mounjaro | Tirzepatide | 106 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 21 |
| Clonazepam | Clonazepam | 96 | 20 |
| Farxiga | Dapagliflozin Propanediol | 96 | 22 |
| Montelukast Sodium | Montelukast Sodium | 96 | 26 |
| Alprazolam | Alprazolam | 91 | 23 |
| Famotidine | Famotidine | 90 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 12 |
| Prednisone | Prednisone | 85 | 69 |
| Pregabalin | Pregabalin | 82 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 20 |
| Carvedilol | Carvedilol | 74 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 20 |
| Meloxicam | Meloxicam | 72 | 22 |
| Ondansetron Odt | Ondansetron | 72 | 23 |
| Mupirocin | Mupirocin | 70 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 12 |
| Belsomra | Suvorexant | 63 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 60 | 39 |
| Chlorthalidone | Chlorthalidone | 57 | 19 |
| Synthroid | Levothyroxine Sodium | 56 | 14 |
| Metformin Hcl Er | Metformin Hcl | 55 | 14 |
| Simvastatin | Simvastatin | 55 | 17 |
| Alendronate Sodium | Alendronate Sodium | 54 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 34 |
| Propranolol Hcl | Propranolol Hcl | 51 | 13 |
| Allopurinol | Allopurinol | 49 | 17 |
| Methylprednisolone | Methylprednisolone | 49 | 36 |
| Hydrocortisone | Hydrocortisone | 47 | 26 |
| Cefuroxime | Cefuroxime Axetil | 46 | 36 |
| Glimepiride | Glimepiride | 45 | 13 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 42 |
| Clotrimazole | Clotrimazole | 42 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | 15 |
| Meclizine Hcl | Meclizine Hcl | 39 | 13 |
| Azithromycin | Azithromycin | 38 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 23 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 22 | 22 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Testosterone | Testosterone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Sucralfate | Sucralfate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $741.74 · 37 records | PFIZER INC. | AIRSUPRA, Auvelity, BEYFORTUS, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fluad, Flucelvax, JOURNAVX, KISUNLA, LINZESS, MENQUADFI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PENBRAYA, PREVNAR 20, Prolastin-C Liquid, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRUMENBA, VAXELIS, VIBERZI, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error